title: Development of an enzymatic pretargeting strategy for dual-modality imaging.
abstract: A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.
authors: CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK. bart.cornelissen@oncology.ox.ac.uk.
authors: J C
authors: JC
authors: Knight
authors: M
authors: M
authors: Mosley
authors: M R L
authors: MR
authors: Stratford
authors: H T
authors: HT
authors: Uyeda
authors: H A
authors: HA
authors: Benink
authors: M
authors: M
authors: Cong
authors: F
authors: F
authors: Fan
authors: S
authors: S
authors: Faulkner
authors: B
authors: B
authors: Cornelissen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000378:metabolism*; D045744:Cell Line, Tumor; D006219:Halogens / Q000378:metabolism*; D006801:Humans; D006867:Hydrolases / Q000378:metabolism*; D008024:Ligands; D061848:Optical Imaging / Q000379:methods*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D006219:Halogens; D008024:Ligands; D006867:Hydrolases; D000068878:Trastuzumab